Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
about
The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemiaPharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline
P2860
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
@ast
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
@en
type
label
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
@ast
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
@en
prefLabel
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
@ast
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
@en
P2093
P2860
P1476
Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline
@en
P2093
Andrew A Somogyi
Benedetta C Sallustio
Benjamin J L Davies
David Gillis
Heather M James
Janet K Coller
Raymond G Morris
P2860
P304
P356
10.1046/J.1365-2125.2003.02033.X
P407
P50
P577
2004-04-01T00:00:00Z